Researchers have discovered a novel mechanism by which normal stromal cells around ovarian cancer cells are converted into cancer-promoting cells. Altering microRNA expression in these cells enhances tumor growth and metastasis, providing new potential therapeutic targets.
A UNM Cancer Center researcher is investigating the link between mitochondrial DNA and ovarian cancer. She hopes to identify genetic markers that could lead to a screening test or therapy, potentially increasing survival rates.
New research reveals that highly metastatic ovarian cancer cells are softer than less aggressive ones, suggesting cell stiffness as a valuable biomarker. This discovery could aid in the development of optimal chemotherapies for various types of cancer.
Women who regularly use aspirin have a decreased risk of serous ovarian cancer, an aggressive form of the disease. However, the benefit must be balanced against potential adverse effects of pain medication use.
Scientists at USC have discovered a new type of drug that works by targeting Protein Disulfide Isomerase (PDI) in ovarian cancer cells. The drug, PACMA31, has shown promise in reducing the number of doses needed and making it effective for patients with resistant cancer.
Researchers at Wake Forest Baptist Medical Center have made a breakthrough in helping infertile, premenopausal women produce enough eggs to become pregnant. By stimulating ovarian cell production using an in vitro rat model, they were able to generate early-stage eggs that could be fertilized.
Researchers at Moffitt Cancer Center have discovered that microRNA miR-214 plays a critical role in regulating ovarian cancer stem cell properties. The study found that miR-214 induces the expression of a stem cell transcription factor (Nanog), leading to chemoresistance and potentially serving as a therapeutic target for ovarian cancer.
A Montreal-based research team has identified genetic patterns in ovarian cancer tumors that relate to patient survival after initial surgery. The study found that patients with mutant p53 protein had longer survival rates compared to those without.
A recent study reveals that basal-like breast tumors and ovarian tumors have similar genetic origins, suggesting potential for shared treatments. The research found unique genetic signatures within each subtype, highlighting the need for personalized cancer therapies.
A study by NIH/National Cancer Institute reveals shared genomic features between high-grade serous ovarian cancer and one subtype of breast cancer. This similarity suggests that the two cancers share a common molecular origin, facilitating comparison of therapeutic data.
A simple three-question paper-and-pencil survey can effectively identify women experiencing symptoms that may indicate ovarian cancer. The study involved 1,200 women and found that the screening tool identified 5% of women with a positive symptom score, resulting in one diagnosis of ovarian cancer.
The US Preventive Services Task Force recommends against annual screening for ovarian cancer in asymptomatic women due to potential harms. Reduced out-of-pocket expenses can improve medication adherence for chronic conditions, with case management and patient education showing strong evidence.
Ovarian cancer cells activate the HOXA9 gene to create an environment that supports tumor growth. Researchers also found blocking TGF-β expression in ovarian cancer cells significantly reduced tumor growth. Additionally, anti-CTLA therapy and inflammation-reversing treatments may hold promise for treating ovarian cancer and alcoholic l...
Researchers found that ovarian cancer cells hijack surrounding tissues by activating the HOXA9 gene, which induces TGF-β production and stimulates tumor growth. Blocking TGF-β expression reduced tumor growth, suggesting potential therapeutic targets for treating ovarian cancer.
The study found that the absence or downregulation of the LRP1B gene is associated with chemoresistance in high-grade serous ovarian cancer. Additionally, tumors that initially responded to chemotherapy but later became resistant evolved further than those that were resistant from the outset.
Lynn and Foster Friess are donating up to $100,000 to support ovarian cancer research at the Translational Genomics Research Institute. The challenge aims to advance cutting-edge genetic technology in pursuit of better cancer treatments.
The European Society of Human Reproduction and Embryology announces a breakthrough in fertility preservation, with Italy's first successful pregnancy and live birth after cryopreserving ovarian tissue. The technique has shown promising results, even after lengthy storage periods.
A new study shows that ovarian grafts can maintain hormonal function for more than seven years in some women, providing a long-term solution for fertility preservation. This breakthrough could benefit young cancer survivors with premature ovarian failure, enabling them to retain reproductive health for an extended period.
A new study by UC Irvine finds significant racial and socioeconomic disparities in ovarian cancer care and survival rates. Poor women and those without insurance face significantly lower survival rates compared to their white and affluent counterparts.
A DNA repair pathway-focused score has been developed to predict chemotherapy response in ovarian cancer patients. The score is positively correlated with complete response rate, recurrence-free survival, and progression-free survival, and outperforms other clinical factors in predicting overall survival.
Scientists have identified bimodal genes acting as molecular switches in ovarian cancer, providing potential targets for clinical prognostic and diagnostic testing. These gene expressions are associated with different tumor subtypes and patient survival outcomes.
A genetic marker in blood can determine if a patient with ovarian cancer will benefit from chemotherapy after surgery. This discovery offers hope to patients diagnosed at stage III of the disease, who have a poor prognosis without effective treatment.
A study analyzing data from 47 studies found that increasing height increases the risk of ovarian cancer by 3% per decade. For body mass index, risks vary depending on whether women have taken menopausal hormone therapy, with an attenuated relationship in never-users.
A CCNY professor is evaluating MabCure Inc.'s monoclonal antibodies as a potential diagnostic reagent for ovarian cancer. The goal is to develop an early detection test that could improve the 94% five-year survival rate of the disease.
Freezing eggs or ovarian tissue for delayed childbearing proves costly for society, with an additional $130,000 required per live birth. The study suggests doing nothing is the most cost-effective option, while freezing eggs is less expensive than ovarian tissue.
Researchers discovered that reduced expression of OGFr accelerates tumorigenesis in human ovarian cancer. The OGF-OGFr axis plays a fundamental role in regulating cell proliferation.
Women with a history of endometriosis are at a significantly higher risk of developing three specific types of ovarian cancer. The study found that endometriosis is linked to a more than threefold chance of developing clear-cell ovarian cancers and over double the risk of developing endometrioid tumours.
A new model of aggressive ovarian cancer reveals that dendritic cells actively support tumor progression, but can be restored to suppress it. Researchers propose targeting dendritic cells to control metastatic ovarian cancer.
A study by Wayne State University School of Medicine researchers found that targeted tumor freezing therapy increases ovarian cancer survival rates, with a 56-month average survival rate reported in 98% of patients. The treatment, called cryoablation, has been shown to be cost-effective, saving an average of $26,806 per life year.
Researchers found a powerful cause-and-effect relationship between elevated platelets and ovarian cancer progression. Tumors stimulate platelet production, which strengthens the disease, reducing survival rates in patients with thrombocytosis.
Scientists at Dana-Farber Cancer Institute have discovered a subtype of ovarian cancer that is susceptible to anti-angiogenic drugs, which block blood vessel formation. The subtype accounts for approximately one-third of all serous ovarian cancers and may benefit from therapies currently being tested in other cancers.
The study aims to determine whether the MYC gene family is involved in the development and chemotherapy-resistance of high-grade serous ovarian cancers. Changes in MYC-family proteins have been identified as a potential cause of at least 15-20 per cent of these cancers, associated with poor clinical outcomes.
Researchers analyzed tumor specimens from 19 advanced stage carcinoma patients, discovering changes in biomarker expression that may impact therapy selection for women with recurrent ovarian cancer. The study highlights the importance of analyzing current tumor tissue to make informed treatment decisions.
The Australian Cancer Research Foundation has committed $2 million to two new cancer research laboratories at the Walter and Eliza Hall Institute. The new facilities will enable researchers to study the biology of epithelial cancers and develop new treatments for breast, ovarian, lung, and leukemia patients.
A study by researchers at H. Lee Moffitt Cancer Center and colleagues identified 27 genes involved in inflammation as related to ovarian cancer risk. The study found that variants in five of these genes, such as IL1A, were associated with lower ovarian cancer risk.
DIM inhibits ovarian cancer cell growth by blocking STAT3 activation and reducing IL-6 levels. The combination of DIM and cisplatin suppresses tumor growth in mice by an extra 50% compared to cisplatin alone.
A study found that women with invasive epithelial ovarian cancer and a BRCA gene mutation had improved 5-year overall survival, with BRCA2 carriers having the best prognosis. The study analyzed data from 26 observational studies and included 1,213 cases with pathogenic germline mutations in BRCA1 or BRCA2.
Researchers reassessed symptom indices to detect ovarian cancer early on, finding similar results to previous reports and a limited benefit in advancing diagnosis. The study highlights the challenges of detecting ovarian cancer early due to its biology, screening limitations, and clinical characteristics.
A study by OHSU Knight Cancer Institute suggests that faulty proteins may be key to identifying new treatments for ovarian cancer. Researchers found that 41% of patients with early disease recurrence had abnormal levels of other proteins, opening up a new direction in treatment.
A clinical trial led by Drs. Amit Oza and Timothy Perren found that treating ovarian cancer with bevacizumab (
A new phase 3 clinical trial shows that targeted therapy bevacizumab effectively delays the progression of advanced ovarian cancer. Patients with newly diagnosed advanced ovarian cancer can now benefit from an additional treatment option, alongside surgery and chemotherapy.
A phase 2 study shows that aflibercept reduces the development of malignant ascites, a common complication of advanced ovarian cancer, and improves symptoms. However, it also increases the risk of fatal bowel perforations.
Researchers identified a DNA methylation site that can detect ovarian cancer recurrence in blood samples, offering potential enhancement to existing biomarkers. This epigenetic marker may help monitor disease status after surgery and improve detection of the disease.
Researchers at Mayo Clinic have found a combination of drugs that destroys 70% of chemotherapy-resistant ovarian cancer cells. The discovery highlights the role of molecule RhoB in tumor response and may help identify patients who benefit from this therapy.
A tiny genetic variation in the KRAS oncogene can predict ovarian cancer outcomes and response to treatment, with women carrying the variant being three times more resistant to standard chemotherapy. The biomarker also increases the risk of poor outcomes in other types of cancer.
Researchers at University of Guelph discovered a peptide that regresses established late-stage tumours in mouse models of ovarian cancer, improving survival rates. The peptide enhances chemotherapy drug delivery, allowing for lower doses and reduced side effects.
A recombinant poxviral vaccine has shown positive responses in both metastatic breast cancer and ovarian cancer, with median overall survival ranging from 13.7 months to 15 months. The treatment led to clinical responses in some patients and mild injection-site reactions as the most common side effect.
A large pad of fat cells in the abdomen provides nutrients that promote the spread and growth of ovarian cancer. Cancer cells reprogram their metabolism to thrive on lipids acquired from fat cells, leading to rapid tumor growth.
Women undergoing IVF treatment have a higher risk of developing borderline ovarian tumours and an increased risk of malignant ovarian cancer compared to those not treated with IVF. The long-term risks are significant enough to warrant further research.
A new genome sequencing method has identified mutations in 12 genes linked to inherited ovarian and related cancers. The test, called BROCA, could become a single test for screening broad range of cancers.
The Terry Fox Research Institute is funding a $5-million program to develop new biomarkers and treatments for ovarian cancer. The program aims to identify new approaches to diagnose and manage the disease, which currently affects one in four women diagnosed with ovarian cancer.
A study found that women with BRCA2 genetic mutations experienced significantly better overall survival rates (61") compared to those without the mutation (25"). Additionally, BRCA2-mutated patients demonstrated longer progression-free survival durations and higher primary chemotherapy sensitivity rates
Women with high-grade ovarian cancer who have BRCA2 genetic mutations live longer and respond better to platinum-based chemotherapy. The tumors are more vulnerable to DNA-damaging agents, which could lead to effective treatment combinations.
A recurrent gene fusion between ESRRA and C11orf20 was found in about 15% of serous ovarian cancer cases, suggesting a potential marker for early detection. The discovery sheds light on how these deadly tumors develop and spread.
Researchers at Stanford University School of Medicine have identified a unique gene fusion in ovarian cancer that could enable early detection and targeted therapies. The fusion, involving genes ESRRA and C11orf20, was found in 15% of aggressive ovarian cancer cases.
A recent study found that depression is a significant barrier to preventive health screening among Latina breast cancer survivors. The research revealed that Hispanic breast cancer patients are more depressed than their non-Hispanic counterparts and have lower rates of screening for colorectal and ovarian cancers.
A new technology developed by Purdue University researchers allows surgeons to detect small clusters of ovarian cancer cells, leading to improved removal rates. The technique uses a fluorescent imaging agent that 'homed' to cancer cells, illuminating their location during surgery.
Researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution of chemotherapy resistance in ovarian cancer. The 'BCL2 antagonist of cell death' (BAD) pathway shows promise as a biomarker to identify patients with high-risk ovarian cancer and potentially reverse chemo-resistance.
A new hybrid imaging device combining photoacoustic imaging, optical coherence tomography, and pulse-echo ultrasound has been developed to diagnose early-stage ovarian cancer. The device was tested on both pig and human ovarian tissue, correctly identifying malignant tumors in initial tests.
Researchers discovered that certain BRCA1 mutations causing hyper-recombination contribute to breast and ovarian cancers by disrupting genomic stability. Targeted therapies may be developed by disrupting ubiquitination to prevent hyper-recombination and kill cancer cells.